GO:0042058 regulation of epidermal growth factor receptor signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0042058 describes any process that modulates the frequency, rate, or extent of epidermal growth factor receptor (EGFR) signaling pathway activity.
• EGFR signaling is controlled at multiple levels, including ligand availability, receptor endocytosis and trafficking, redox-dependent modification, and microRNA-mediated silencing.
• Dysregulation of EGFR signaling regulation is central to many cancers, including colorectal, mammary, cervical, and other tumor types.
• Key regulatory nodes include EGF-family ligands such as EREG, the EGFR receptor itself, endocytic machinery, redox enzymes, and microRNAs.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable causal dissection of regulatory mechanisms within this GO term.
• Understanding GO:0042058 has therapeutic implications, as EGFR-targeted inhibitors and microRNA-based strategies are under active investigation.
Description
The epidermal growth factor receptor (EGFR) signaling pathway is one of the most extensively studied signal transduction cascades in cell biology, controlling proliferation, survival, migration, and differentiation. The Gene Ontology term GO:0042058, regulation of epidermal growth factor receptor signaling pathway, captures the diverse molecular processes that modulate the frequency, rate, or extent of this pathway's activity. Because EGFR signaling is tightly regulated under normal physiology, its dysregulation is a hallmark of many human diseases, particularly cancer. Researchers studying this term aim to identify the specific regulators, mechanisms, and contexts that control EGFR pathway output. Regulation of EGFR signaling occurs at multiple levels, from ligand bioavailability and receptor endocytosis to post-translational modifications and microRNA-mediated silencing. For example, endocytic trafficking determines whether activated EGFR is recycled to the plasma membrane or degraded, thereby shaping signal duration and intensity. Redox-dependent modifications of EGFR can also modulate its activity in response to cellular oxidative state. Additionally, microRNAs can directly target EGFR or its downstream effectors, adding another layer of regulatory control. Given the pathway's central role in cancer and other diseases, understanding GO:0042058 is critical for both basic and translational research. This article synthesizes authoritative QuickGO data and verified PubMed literature to provide a research-grade overview of the mechanisms, key genes, disease links, and experimental methods relevant to this GO term.
regulation of epidermal growth factor receptor signaling pathway At A Glance
| GO ID | GO:0042058 |
|---|---|
| GO term | regulation of epidermal growth factor receptor signaling pathway |
| Ontology | biological_process |
| Synonym | regulation of EGF receptor signaling pathway; regulation of EGF receptor signalling pathway; regulation of EGFR signaling pathway |
| Definition | Any process that modulates the frequency, rate or extent of epidermal growth factor receptor signaling pathway activity. |
| Major function | Modulation of EGFR signaling intensity, duration, and spatial distribution. |
| Related processes | Endocytosis, redox regulation, microRNA-mediated silencing, ligand processing. |
| Disease relevance | Cancer (colorectal, mammary, cervical), sleep regulation, and other pathologies. |
What Is GO:0042058?
GO:0042058, regulation of epidermal growth factor receptor signaling pathway, is defined as any process that modulates the frequency, rate, or extent of epidermal growth factor receptor signaling pathway activity. This biological process encompasses both positive and negative regulation, including changes in ligand availability, receptor trafficking, post-translational modifications, and downstream signaling modulation.
Why Is regulation of epidermal growth factor receptor signaling pathway Important in Cell Biology?
GO:0042058 is important because EGFR signaling is a master regulator of cell proliferation, survival, and migration, and its dysregulation drives numerous cancers and other diseases. Understanding how this pathway is regulated provides mechanistic insights into disease pathogenesis and identifies potential therapeutic targets, such as microRNAs, endocytic regulators, and redox modulators.
• EGFR signaling is frequently hyperactivated in cancers, making its regulation a key therapeutic focus.
• MicroRNAs that regulate EGFR signaling are potential biomarkers and therapeutic agents in cervical and other cancers.
• Redox-dependent regulation of EGFR links cellular oxidative stress to growth factor signaling.
• Endocytic trafficking determines EGFR signal duration and is critical for normal development and tissue homeostasis.
• EREG/EGFR pathway regulation influences tumor progression and is a target in colorectal cancer.
• EGFR signaling regulates evolutionarily conserved sleep behavior, highlighting its role beyond cancer.
• Regorafenib suppresses EGFR signaling-modulated colorectal cancer progression, demonstrating clinical relevance.
• Targeting EGFR signaling in mammary cancer is an active area of drug development.
• CRISPR-based models allow precise dissection of regulatory mechanisms within this GO term.
What Happens During regulation of epidermal growth factor receptor signaling pathway?
Ligand Availability and Receptor Activation
In simple terms: The amount of growth factor ligand available to bind EGFR controls how strongly the pathway is switched on.
Regulation of EGFR signaling begins with the availability of EGF-family ligands such as EGF, TGF-alpha, and EREG. Ligand binding induces receptor dimerization and autophosphorylation, initiating downstream signaling. The expression levels of these ligands, as well as their processing and release, are key regulatory points. For example, EREG overexpression can enhance EGFR signaling in tumor progression.
Endocytic Trafficking and Receptor Degradation
In simple terms: After activation, the receptor is internalized and either recycled back to the cell surface or degraded, which determines how long the signal lasts.
Spatial regulation of EGFR signaling by endocytosis is a major mechanism controlling signal duration and intensity. Upon activation, EGFR is internalized into endosomes, where it can either be recycled to the plasma membrane or sorted to lysosomes for degradation. This trafficking decision is regulated by ubiquitination, ESCRT components, and Rab GTPases. Dysregulation of endocytic trafficking can lead to sustained EGFR signaling, contributing to oncogenesis.
Redox-Dependent Modulation
In simple terms: Chemical modifications caused by reactive oxygen species can directly alter EGFR activity.
Redox-dependent regulation of EGFR signaling involves reversible oxidation of cysteine residues in the receptor, which can modulate its kinase activity and downstream signaling. This links cellular redox state to growth factor signaling, with implications for cancer and inflammatory diseases. Enzymes such as NADPH oxidases and antioxidant systems participate in this regulation.
MicroRNA-Mediated Silencing
In simple terms: Small RNA molecules can bind to EGFR messenger RNA and reduce its production, dampening the pathway.
MicroRNAs (miRNAs) regulate EGFR signaling by targeting EGFR mRNA or mRNAs of downstream effectors for degradation or translational repression. In cervical cancer, specific miRNAs have been shown to modulate EGFR pathway activity, affecting tumor cell proliferation and survival. This layer of regulation adds complexity and offers opportunities for RNA-based therapeutics.
Downstream Feedback and Crosstalk
In simple terms: The pathway has built-in brakes and interactions with other signaling systems that fine-tune its output.
EGFR signaling is subject to negative feedback loops, such as ERK-mediated phosphorylation of EGFR or downstream adaptors, which attenuate the signal. Additionally, crosstalk with other receptor tyrosine kinases and G-protein coupled receptors can modulate EGFR pathway activity. These feedback mechanisms are often disrupted in cancer, leading to sustained signaling.
Key Genes Involved in GO:0042058 regulation of epidermal growth factor receptor signaling pathway
The following genes and proteins are central to the regulation of EGFR signaling (GO:0042058), as supported by the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| EGFR | Receptor tyrosine kinase that initiates the pathway | Primary target of regulatory mechanisms and therapeutic inhibitors |
| EGF | Ligand that activates EGFR | Controls pathway activation via availability |
| EREG | EGFR ligand involved in tumor progression | Overexpression enhances EGFR signaling in cancer |
| TGF-alpha | EGFR ligand | Regulates receptor activation in various tissues |
| MIR-XXX (miRNAs) | Post-transcriptional silencing of EGFR or effectors | Modulate pathway in cervical cancer |
| CBL | E3 ubiquitin ligase that ubiquitinates EGFR | Regulates receptor endocytosis and degradation |
| RAB5 | GTPase controlling early endosome fusion | Affects EGFR trafficking and signal duration |
| RAB7 | GTPase controlling late endosome/lysosome trafficking | Determines EGFR degradation |
| ESCRT components | Sort ubiquitinated EGFR into intraluminal vesicles | Regulate receptor downregulation |
| NOX enzymes | NADPH oxidases producing reactive oxygen species | Mediate redox-dependent EGFR regulation |
| PTPs (e.g., PTP1B) | Protein tyrosine phosphatases that dephosphorylate EGFR | Negative regulators of EGFR signaling |
| ERK | Downstream kinase in MAPK cascade | Mediates feedback phosphorylation of EGFR |
| AKT | Downstream kinase in PI3K pathway | Survival signaling downstream of EGFR |
| STAT3 | Transcription factor activated by EGFR | Regulates gene expression and feedback |
| GRB2 | Adaptor protein binding phosphotyrosine on EGFR | Links EGFR to RAS-MAPK pathway |
| SOS | Guanine nucleotide exchange factor for RAS | Activates RAS downstream of EGFR |
| PTEN | Lipid phosphatase antagonizing PI3K | Indirectly regulates EGFR signaling output |
How Is regulation of epidermal growth factor receptor signaling pathway Regulated?
Regulation of EGFR signaling is itself a highly regulated process. Key regulatory inputs include microRNAs that target EGFR mRNA, redox-dependent modifications that alter receptor activity, and endocytic trafficking that controls receptor fate. Additionally, feedback phosphorylation by downstream kinases such as ERK can attenuate receptor activity. These layers ensure appropriate signal amplitude and duration in normal cells, and their disruption contributes to disease.
regulation of epidermal growth factor receptor signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| EGFR | Colorectal cancer, mammary cancer | Knockout or point-mutation cell lines |
| EREG | Tumor progression | Overexpression models |
| MIR-XXX | Cervical cancer | Knock-in or overexpression of miRNA |
| CBL | Cancer (impaired EGFR degradation) | Knockout of CBL in cancer cells |
| NOX enzymes | Redox-related diseases | Knockout or point mutation of NOX isoforms |
Cancer
Dysregulation of EGFR signaling regulation is a hallmark of many cancers. In colorectal cancer, regorafenib suppresses EGFR signaling-modulated progression, highlighting the therapeutic potential of targeting this pathway. In mammary cancer, advances in targeting EGFR signaling have led to several approved inhibitors. Cervical cancer also features microRNA-mediated regulation of EGFR signaling, offering opportunities for RNA-based therapies. EREG/EGFR pathway overactivation promotes tumor progression in multiple cancer types.
Sleep and Neurological Function
Evolutionarily conserved regulation of sleep by EGFR signaling has been demonstrated, indicating that this pathway influences behavioral states beyond cell growth. This suggests that regulators of EGFR signaling may also play roles in neurological function and sleep disorders.
Redox-Related Pathologies
Redox-dependent regulation of EGFR signaling links oxidative stress to growth factor signaling, with implications for cancer, inflammation, and neurodegenerative diseases. Modulating redox regulators could therefore influence EGFR pathway output in disease contexts.
From regulation of epidermal growth factor receptor signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate regulator alter EGFR signaling? | CRISPR knockout cell line |
| Does a specific point mutation in EGFR affect its regulation? | CRISPR point mutation knock-in |
| Does tagging an endogenous regulator affect its function? | Tagged knock-in (e.g., GFP) |
| Does overexpression of a ligand enhance pathway activity? | CRISPR overexpression (e.g., CRISPRa) |
| Which microRNAs regulate EGFR signaling? | miRNA overexpression or knockout |
| How does redox modification affect EGFR? | Point mutation of cysteine residues |
How to Study the regulation of epidermal growth factor receptor signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Transcriptome changes | Identify genes regulated by EGFR signaling |
| Phosphoproteomics | Phosphorylation events | Quantify EGFR and downstream phosphorylation |
| Live-cell imaging | Receptor trafficking | Track EGFR endocytosis and recycling |
| CRISPR screening | Gene essentiality and regulators | Discover novel regulators of EGFR signaling |
| Luciferase reporter | Pathway activity | Measure EGFR-driven transcription |
| Proliferation assay | Cell growth | Assess functional impact of regulators |
| miRNA profiling | microRNA expression | Identify miRNAs targeting EGFR pathway |
| Redox sensors | Reactive oxygen species | Measure redox state affecting EGFR |
Genomic and Transcriptomic Approaches
RNA-seq and microarray analyses can identify changes in gene expression upon perturbation of EGFR signaling regulators. CRISPR screening combined with RNA-seq enables unbiased discovery of regulators.
Proteomic and Phosphoproteomic Methods
Mass spectrometry-based phosphoproteomics can quantify changes in EGFR phosphorylation and downstream signaling upon regulatory perturbations. Proximity labeling can identify interactors of EGFR in endosomes.
Imaging and Trafficking Assays
Fluorescence microscopy and live-cell imaging can track EGFR internalization, recycling, and degradation in response to regulatory cues. Total internal reflection fluorescence (TIRF) microscopy is useful for studying receptor dynamics at the plasma membrane.
Functional Assays
Proliferation, migration, and apoptosis assays can measure the functional consequences of altered EGFR signaling regulation. Reporter assays for downstream transcription factors (e.g., STAT3, ELK1) can quantify pathway activity.
How CRISPR Can Be Used to Study GO:0042058 regulation of epidermal growth factor receptor signaling pathway
Knockout
CRISPR knockout of candidate regulatory genes (e.g., CBL, RAB5) can determine their necessity for EGFR signaling regulation. Knockout cell lines are valuable for studying loss-of-function phenotypes in cancer models.
Point Mutation
Introducing specific point mutations (e.g., in EGFR phosphorylation sites or cysteine residues) via CRISPR allows precise dissection of regulatory mechanisms. This is particularly useful for studying redox-sensitive residues.
Knock-in
Knock-in of tagged versions of EGFR or its regulators (e.g., GFP, HA) enables visualization and biochemical isolation of endogenous complexes. Knock-in of disease-associated mutations can model cancer variants.
Overexpression
CRISPR activation (CRISPRa) or cDNA overexpression can elevate levels of ligands (e.g., EREG) or regulators to study gain-of-function effects on EGFR signaling. This is useful for modeling ligand-driven tumors.
How EDITGENE Supports regulation of epidermal growth factor receptor signaling pathway Research
Researchers studying regulation of epidermal growth factor receptor signaling pathway-related genes often need to determine whether a candidate gene is causally involved in modulating pathway activity. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such investigations, from knockout to precise point mutations and overexpression models.
Contact EDITGENE today to design your custom CRISPR model for regulation of epidermal growth factor receptor signaling pathway research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| CEACAM1 Knockout HEK293 Cell Line | EDJ-KQ268 | Human | 634 | Details Get a Quote |
| MVB12A Knockout HEK293 Cell Line | EDJ-KQ1945 | Human | 93343 | Details Get a Quote |
| PTPN12 Knockout HEK293 Cell Line | EDJ-KQ2400 | Human | 5782 | Details Get a Quote |
| CDH13 Knockout HEK293 Cell Line | EDJ-KQ4242 | Human | 1012 | Details Get a Quote |
| FER Knockout HEK293 Cell Line | EDJ-KQ4594 | Human | 2241 | Details Get a Quote |
| MVB12B Knockout HEK293 Cell Line | EDJ-KQ9801 | Human | 89853 | Details Get a Quote |
| WDR54 Knockout HEK293 Cell Line | EDJ-KQ9961 | Human | 84058 | Details Get a Quote |
| RHBDF1 Knockout HEK293 Cell Line | EDC90135 | Human | 64285 | Details Get a Quote |
| RHBDF2 Knockout HEK293 Cell Line | EDC07822 | Human | 79651 | Details Get a Quote |
| FER Knockout HCT 116 Cell Line | EDJ-KQ26004 | Human | 2241 | Details Get a Quote |
| MVB12B Knockout A-549 Cell Line | EDJ-KQ37936 | Human | 89853 | Details Get a Quote |
| MVB12B Knockout HCT 116 Cell Line | EDJ-KQ37937 | Human | 89853 | Details Get a Quote |
| MVB12B Knockout HeLa Cell Line | EDJ-KQ37938 | Human | 89853 | Details Get a Quote |
| MVB12A Knockout HeLa Cell Line | EDJ-KQ20591 | Human | 93343 | Details Get a Quote |
| MVB12A Knockout A-549 Cell Line | EDJ-KQ21884 | Human | 93343 | Details Get a Quote |
- 1
- 2
- Next Page »
Frequently Asked Questions About regulation of epidermal growth factor receptor signaling pathway
What is GO:0042058?
GO:0042058 is the Gene Ontology term for regulation of epidermal growth factor receptor signaling pathway, defined as any process that modulates the frequency, rate, or extent of EGFR signaling activity.
What genes are involved in regulation of EGFR signaling?
Key genes include EGFR, EGF, EREG, CBL, RAB5, RAB7, ESCRT components, NOX enzymes, and various microRNAs.
How is EGFR signaling regulated by endocytosis?
Endocytosis controls EGFR signal duration by sorting activated receptors to recycling endosomes or lysosomes for degradation.
What role do microRNAs play in EGFR signaling?
MicroRNAs can target EGFR mRNA or downstream effectors, reducing pathway activity and influencing cancer progression.
How does redox regulation affect EGFR?
Reactive oxygen species can reversibly oxidize cysteine residues in EGFR, modulating its kinase activity and downstream signaling.
Is EGFR signaling regulation important in cancer?
Yes, dysregulation of EGFR signaling regulation is common in many cancers, including colorectal, mammary, and cervical cancers.
What experimental models are used to study GO:0042058?
CRISPR knockout, point mutation, knock-in, and overexpression cell models, as well as animal models, are widely used.
What is the role of EREG in EGFR signaling?
EREG is an EGFR ligand whose overexpression enhances EGFR signaling and promotes tumor progression.
How can CRISPR help study EGFR signaling regulation?
CRISPR enables precise genetic perturbations to test causality of candidate regulators in EGFR signaling.
Does EGFR signaling regulate sleep?
Yes, evolutionarily conserved regulation of sleep by EGFR signaling has been demonstrated in animal models.
Conclusion
GO:0042058, regulation of epidermal growth factor receptor signaling pathway, encompasses a complex network of molecular mechanisms that fine-tune EGFR signal output. From ligand availability and endocytic trafficking to redox modification and microRNA silencing, these regulatory layers are critical for normal physiology and are frequently disrupted in diseases such as cancer. Continued research using CRISPR-based models and advanced omics will further illuminate these mechanisms and inform therapeutic strategies.
References
- 1. Sabbah DA et al.. 2020. Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors.. Curr Top Med Chem 20(10):815-834 PMID: 32124699
- 2. Hemmat N et al.. 2020. Role of microRNAs in epidermal growth factor receptor signaling pathway in cervical cancer.. Mol Biol Rep 47(6):4553-4568 PMID: 32383136
- 3. Heppner DE et al.. 2016. Redox-dependent regulation of epidermal growth factor receptor signaling.. Redox Biol 8:24-7 PMID: 26722841
- 4. Cheng WL et al.. 2021. The Role of EREG/EGFR Pathway in Tumor Progression.. Int J Mol Sci 22(23) PMID: 34884633
- 5. Ceresa BP. 2012. Spatial regulation of epidermal growth factor receptor signaling by endocytosis.. Int J Mol Sci 14(1):72-87 PMID: 23344022
- 6. Lee DA et al.. 2019. Evolutionarily conserved regulation of sleep by epidermal growth factor receptor signaling.. Sci Adv 5(11):eaax4249 PMID: 31763451
- 7. Liu YC et al.. 2020. Regorafenib suppresses epidermal growth factor receptor signaling-modulated progression of colorectal cancer.. Biomed Pharmacother 128:110319 PMID: 32502841
- 8. Kyriakopoulou K et al.. 2018. Advances in targeting epidermal growth factor receptor signaling pathway in mammary cancer.. Cell Signal 51:99-109 PMID: 30071291
